Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Stroke 1Precancerous Conditions 1Neoplasms 1Melanoma 1Liver Cirrhosis 1Ischemic Attack, Transient 1Healthy Participants 1Colorectal Neoplasms 1Colonic Neoplasms 1Cardiovascular Diseases 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Atherosclerosis 1Adenomatous Polyps 1

Interventions

Trastuzumab 243Paclitaxel 193Cyclophosphamide 158Docetaxel 134Letrozole 113Capecitabine 113Fulvestrant 106Doxorubicin 103Bevacizumab 87Carboplatin 81exemestane 80Anastrozole 79Lapatinib 70Tamoxifen 69Albumin-Bound Paclitaxel 57palbociclib 54pertuzumab 53Taxes 51Gemcitabine 50Radiotherapy 46eribulin 43pembrolizumab 41Everolimus 41Ado-Trastuzumab Emtansine 41Vinorelbine 38130-nm albumin-bound paclitaxel 35ixabepilone 32Epirubicin 28pegfilgrastim 25liposomal doxorubicin 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Breast Neoplasms × Rosuvastatin Calcium × Clear all
NCT01299038 2020-02-05

Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
20 enrolled 4 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡